Monopar Therapeutics (MNPR) Shareholders’ equity 2016–2025
Monopar Therapeutics (MNPR) shareholders’ equity at each fiscal year-end, per SEC filings.
$137.8MFY2025 · since FY2016: $2.8M → $137.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $137.8M | +150.4% |
| FY2024 | $55.0M | — |
| FY2019 | $12.6M | +82.5% |
| FY2018 | $6.9M | -28.1% |
| FY2017 | $9.6M | +239.8% |
| FY2016 | $2.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice